You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEtidronic acid
Accession NumberDB01077  (APRD00964)
TypeSmall Molecule
GroupsApproved
DescriptionA diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover. [PubChem]
Structure
Thumb
Synonyms
(1-hydroxy-ethylidene)diphosphonic acid
(1-Hydroxyethylene)diphosphonic acid
(1-Hydroxyethylidene)bis(phosphonic acid)
(1-Hydroxyethylidene)bisphosphonic acid
(1-Hydroxyethylidene)diphosphonic acid
(Hydroxyethylidene)diphosphonic acid
1-Hydroxy-1,1-diphosphonoethane
1-hydroxyethane 1,1-diphosphonic acid
1-Hydroxyethane-1,1-bisphosphonic acid
1-Hydroxyethane-1,1-diphosphonate
1-Hydroxyethane-1,1-diphosphonic acid
1-Hydroxyethanediphosphonic acid
1-Hydroxyethylidene-1,1-bisphosphonate
1-Hydroxyethylidene-1,1-diphosphonic acid
1,1,1-Ethanetriol diphosphonate
Acetodiphosphonic acid
acide étidronique
ácido etidrónico
acidum etidronicum
EHDP
Ethane-1-hydroxy-1,1-bisphosphonic acid
Ethane-1-hydroxy-1,1-diphosphonate
Ethane-1-hydroxy-1,1-diphosphonic acid
Etidronate
Etidronsäure
HEDP
Hydroxyethanediphosphonic acid
Oxyethylidenediphosphonic acid
External Identifiers
  • NSC-227995
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Etidronatetablet400 mgoralActavis Pharma CompanyNot applicableNot applicableCanada
Act Etidronatetablet200 mgoralActavis Pharma Company2004-11-10Not applicableCanada
Didronel Inj 50mg/mlsolution50 mgintravenousMgi Pharma Inc.1991-12-312004-09-30Canada
Didronel Tab 200mgtablet200 mgoralProcter & Gamble Pharmaceuticals Canada Inc1993-12-312010-07-07Canada
Etidronatetablet200 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Etidronatetablet400 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Mylan-etidronatetablet200 mgoralMylan Pharmaceuticals Ulc2003-06-04Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-etidronatetablet400 mgoralApotex IncNot applicableNot applicableCanada
Apo-etidronatetablet200 mgoralApotex IncNot applicableNot applicableCanada
Etidronate Disodiumtablet200 mg/1oralMylan Pharmaceuticals Inc.2008-01-02Not applicableUs
Etidronate Disodiumtablet400 mg/1oralMylan Pharmaceuticals Inc.2008-01-02Not applicableUs
Etidronate Disodiumtablet200 mg/1oralCarilion Materials Management2008-01-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DidronelProcter & Gamble
EtidronGentili
Brand mixtures
NameLabellerIngredients
Act EtidrocalActavis Pharma Company
DidrocalWarner Chilcott Canada Co
EtidrocalSanis Health Inc
Mylan-eti-cal CarepacMylan Pharmaceuticals Ulc
Novo-etidronatecalTeva Canada Limited
Ntp-etidronate CalciumTeva Canada Limited
Salts
Name/CASStructureProperties
Etidronate disodium
7414-83-7
Thumb
  • InChI Key: GWBBVOVXJZATQQ-UHFFFAOYSA-L
  • Monoisotopic Mass: 249.93841492
  • Average Mass: 249.9919
DBSALT000842
Categories
UNIIM2F465ROXU
CAS number2809-21-4
WeightAverage: 206.0282
Monoisotopic: 205.974525634
Chemical FormulaC2H8O7P2
InChI KeyDBVJJBKOTRCVKF-UHFFFAOYSA-N
InChI
InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)
IUPAC Name
(1-hydroxy-1-phosphonoethyl)phosphonic acid
SMILES
CC(O)(P(O)(O)=O)P(O)(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
KingdomOrganic compounds
Super ClassOrganophosphorus compounds
ClassOrganic phosphonic acids and derivatives
Sub ClassBisphosphonates
Direct ParentBisphosphonates
Alternative Parents
Substituents
  • Bisphosphonate
  • Organophosphonic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury.
PharmacodynamicsEtidronic acid is a first generation (non-nitrogenous) bisphosphonate in the same family as clodronate and tiludronate. Etidronic acid affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the etidronic acid that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface. Etidronic acid has been shown to prevent or delay skeletal-related events and decrease bone pain as well as normalize calcium levels in the presence of hypercalcemia.
Mechanism of actionBisphosphonates, when attached to bone tissue, are absorbed by osteoclasts, the bone cells that breaks down bone tissue. Although the mechanism of action of non-nitrogenous bisphosphonates has not been fully elucidated, available data suggest that they bind strongly to hydroxyapatite crystals in the bone matrix, preferentially at the sites of increased bone turnover and inhibit the formation and dissolution of the crystals. Other actions may include direct inhibition of mature osteoclast function, promotion of osteoclast apoptosis, and interference with osteoblast-mediated osteoclast activation. Etidronic acid does not interfere with bone mineralization. In malignancy-related hypercalcemia, etidronic acid decreases serum calcium by inhibiting tumour-induced bone resorption and reducing calcium flow from the resorbing bone into the blood. Etidronic acid also reduces morbidity of osteolytic bone metastases by inhibiting tumour-induced bone resorption. Etidronic acid may promote osteoclast apoptosis by competing with adenosine triphosphate (ATP) in the cellular energy metabolism. The osteoclast initiates apoptosis and dies, leading to an overall decrease in the breakdown of bone.
Related Articles
AbsorptionThe amount of drug absorbed after an oral dose is approximately 3%.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Not metabolized.

Route of eliminationEtidronate disodium is not metabolized. Within 24 hours, approximately half the absorbed dose is excreted in urine; the remainder is distributed to bone compartments from which it is slowly eliminated. Unabsorbed drug is excreted intact in the feces.
Half lifeIn normal subjects, plasma half-life of etidronic acid, based on non-compartmental pharmacokinetics is 1 to 6 hours.
ClearanceNot Available
ToxicityClinical experience with acute etidronic acid overdosage is extremely limited. Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients. Some patients may develop vomiting. In one event, an 18-year-old female who ingested an estimated single dose of 4800 to 6000 mg (67 to 100 mg/kg) of etidronate was reported to be mildly hypocalcemic (7 .5 2 mg/ dl) and experienced paresthesia of the fingers.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8918
Blood Brain Barrier+0.8901
Caco-2 permeable-0.8581
P-glycoprotein substrateNon-substrate0.7483
P-glycoprotein inhibitor INon-inhibitor0.9639
P-glycoprotein inhibitor IINon-inhibitor0.9951
Renal organic cation transporterNon-inhibitor0.9726
CYP450 2C9 substrateNon-substrate0.7545
CYP450 2D6 substrateNon-substrate0.8473
CYP450 3A4 substrateNon-substrate0.6987
CYP450 1A2 substrateNon-inhibitor0.9061
CYP450 2C9 inhibitorNon-inhibitor0.9047
CYP450 2D6 inhibitorNon-inhibitor0.9222
CYP450 2C19 inhibitorNon-inhibitor0.9186
CYP450 3A4 inhibitorNon-inhibitor0.9595
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9873
Ames testNon AMES toxic0.8875
CarcinogenicityCarcinogens 0.5282
BiodegradationNot ready biodegradable0.7701
Rat acute toxicity1.9653 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9519
hERG inhibition (predictor II)Non-inhibitor0.9495
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral400 mg
Solutionintravenous50 mg
Tabletoral200 mg/1
Tabletoral400 mg/1
Kit; tabletoral
Tabletoral200 mg
Prices
Unit descriptionCostUnit
Didronel 400 mg tablet8.31USD tablet
Didronel 200 mg tablet4.16USD tablet
Co Etidronate 200 mg Tablet0.86USD tablet
Mylan-Etidronate 200 mg Tablet0.86USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.5 mg/mLALOGPS
logP-0.77ALOGPS
logP-2.3ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)0.7ChemAxon
pKa (Strongest Basic)-5.1ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area135.29 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity34.51 m3·mol-1ChemAxon
Polarizability13.97 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Rogovin, L.,Brawn, D.P. and Kalberg, AN.; US. Patent 3,400,147; September 3,1968; assigned to The Procter & Gamble Co.

General ReferencesNot Available
External Links
ATC CodesM05BB01M05BA01
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (42 KB)
MSDSDownload (44.4 KB)
Interactions
Drug Interactions
Drug
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Etidronic acid.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Etidronic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Etidronic acid.
Aluminum hydroxideThe serum concentration of Etidronic acid can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Etidronic acid can be decreased when it is combined with Aluminum phosphate.
AmikacinAmikacin may increase the hypocalcemic activities of Etidronic acid.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Etidronic acid.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Etidronic acid.
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etidronic acid.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Etidronic acid.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Etidronic acid.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Etidronic acid.
Bismuth SubcitrateThe serum concentration of Etidronic acid can be decreased when it is combined with Bismuth Subcitrate.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Etidronic acid.
Calcium carbonateThe serum concentration of Etidronic acid can be decreased when it is combined with Calcium carbonate.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Etidronic acid.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Etidronic acid.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etidronic acid.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Etidronic acid.
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Etidronic acid.
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Etidronic acid.
DaunorubicinDaunorubicin may increase the hypocalcemic activities of Etidronic acid.
DeferasiroxThe risk or severity of adverse effects can be increased when Etidronic acid is combined with Deferasirox.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Etidronic acid.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Etidronic acid.
DihydrostreptomycinDihydrostreptomycin may increase the hypocalcemic activities of Etidronic acid.
DoxorubicinDoxorubicin may increase the hypocalcemic activities of Etidronic acid.
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Etidronic acid.
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Etidronic acid.
EpirubicinEpirubicin may increase the hypocalcemic activities of Etidronic acid.
EsomeprazoleThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Esomeprazole.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Etidronic acid.
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Etidronic acid.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Etidronic acid.
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Etidronic acid.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Etidronic acid.
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Etidronic acid.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Etidronic acid.
Ferric CitrateThe serum concentration of Etidronic acid can be decreased when it is combined with Ferric Citrate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Etidronic acid.
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Etidronic acid.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Etidronic acid.
FramycetinFramycetin may increase the hypocalcemic activities of Etidronic acid.
GentamicinGentamicin may increase the hypocalcemic activities of Etidronic acid.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Etidronic acid.
Hygromycin BHygromycin B may increase the hypocalcemic activities of Etidronic acid.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Etidronic acid.
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Etidronic acid.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Etidronic acid.
IdarubicinIdarubicin may increase the hypocalcemic activities of Etidronic acid.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Etidronic acid.
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Etidronic acid.
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Etidronic acid.
KanamycinKanamycin may increase the hypocalcemic activities of Etidronic acid.
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Etidronic acid.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Etidronic acid.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etidronic acid.
LansoprazoleThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Lansoprazole.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Etidronic acid.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Etidronic acid.
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Etidronic acid.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Etidronic acid.
Magnesium carbonateThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Etidronic acid.
Magnesium SulfateThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium Sulfate.
Magnesium TrisilicateThe serum concentration of Etidronic acid can be decreased when it is combined with Magnesium Trisilicate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Etidronic acid.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Etidronic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Etidronic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Etidronic acid.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Etidronic acid.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Etidronic acid.
MetrizamideMetrizamide may increase the hypocalcemic activities of Etidronic acid.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etidronic acid.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etidronic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Etidronic acid.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Etidronic acid.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Etidronic acid.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Etidronic acid.
NeomycinNeomycin may increase the hypocalcemic activities of Etidronic acid.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Etidronic acid.
NetilmicinNetilmicin may increase the hypocalcemic activities of Etidronic acid.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Etidronic acid.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etidronic acid.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etidronic acid.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etidronic acid.
OmeprazoleThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Etidronic acid.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Etidronic acid.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Etidronic acid.
PantoprazoleThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Pantoprazole.
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Etidronic acid.
ParomomycinParomomycin may increase the hypocalcemic activities of Etidronic acid.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Etidronic acid.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etidronic acid.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Etidronic acid.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Etidronic acid.
PlicamycinPlicamycin may increase the hypocalcemic activities of Etidronic acid.
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Etidronic acid.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Etidronic acid.
PuromycinPuromycin may increase the hypocalcemic activities of Etidronic acid.
RabeprazoleThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Rabeprazole.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Etidronic acid.
RibostamycinRibostamycin may increase the hypocalcemic activities of Etidronic acid.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Etidronic acid.
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Etidronic acid.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Etidronic acid.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Etidronic acid.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Etidronic acid.
SpectinomycinSpectinomycin may increase the hypocalcemic activities of Etidronic acid.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Etidronic acid.
StreptomycinStreptomycin may increase the hypocalcemic activities of Etidronic acid.
StreptozocinStreptozocin may increase the hypocalcemic activities of Etidronic acid.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etidronic acid.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Etidronic acid.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Etidronic acid.
TAK-390MRThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with TAK-390MR.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Etidronic acid.
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Etidronic acid.
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Etidronic acid.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Etidronic acid.
TobramycinTobramycin may increase the hypocalcemic activities of Etidronic acid.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Etidronic acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Etidronic acid.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Etidronic acid.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etidronic acid.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Etidronic acid.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Etidronic acid.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Etidronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Etidronic acid.
Food Interactions
  • Avoid aluminium, calcium, iron and magnesium within 2 hours of taking medication.
  • Take on an empty stomach with a full glass of water.

Targets

Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
antagonist
References
  1. Grases F, Sanchis P, Perello J, Isern B, Prieto RM, Fernandez-Palomeque C, Torres JJ: Effect of crystallization inhibitors on vascular calcifications induced by vitamin D: a pilot study in Sprague-Dawley rats. Circ J. 2007 Jul;71(7):1152-6. [PubMed:17587727 ]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206 ]
  3. Ono K, Wada S: [Regulation of calcification by bisphosphonates]. Clin Calcium. 2004 Jun;14(6):60-3. [PubMed:15577056 ]
  4. Takaishi Y: [Treatment of periodontal disease, prevention and bisphosphonate]. Clin Calcium. 2003 Feb;13(2):173-6. [PubMed:15775080 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine phosphatase activity
Specific Function:
Interacts with LAR-interacting protein LIP.1.
Gene Name:
PTPRS
Uniprot ID:
Q13332
Molecular Weight:
217039.825 Da
References
  1. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran C, Rodan SB, Rodan GA: Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):3068-73. [PubMed:8610169 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Proton-transporting atpase activity, rotational mechanism
Specific Function:
Catalytic subunit of the peripheral V1 complex of vacuolar ATPase. V-ATPase vacuolar ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.
Gene Name:
ATP6V1A
Uniprot ID:
P38606
Molecular Weight:
68303.5 Da
References
  1. David P, Nguyen H, Barbier A, Baron R: The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res. 1996 Oct;11(10):1498-507. [PubMed:8889850 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23